
|Videos|September 18, 2017
Exploring Cabozantinib With Nivolumab and Ipilimumab in Urothelial Carcinoma
Author(s)Andrea B. Apolo, MD
Andrea B. Apolo, MD, principal investigator and the head of the Bladder Cancer Section in the Genitourinary Malignancies Branch at the National Cancer Institute’s Center for Cancer Research, discusses a phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and cabozantinib plus nivolumab with ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma and other genitourinary tumors.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: Lung Cancer Advancements and FDA Decisions
2
Nivolumab Outperforms Brentuximab Vedotin in PFS in Classic Hodgkin Lymphoma
3
Savolitinib/Osimertinib Extends PFS in MET-Amplified EGFR-Mutated NSCLC
4
Second-Line Therapy and Ruxolitinib for cGVHD
5













































